Navigation Links
Cellular Dynamics Raises $30 Million to Expand Its Product Line of Human Stem Cells and Tissue Cells

MADISON, Wis., April 7, 2011 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), the world's only industrial manufacturer of human induced pluripotent stem cells (iPSCs) and tissue cells, has closed on a $30 million private equity round. This recent Series B Preferred Stock financing was led by an entity affiliated with Tactics II Stem Cell Ventures, which along with its affiliates led CDI's prior capital raises. Other investors in this financing round include Sam Zell's Equity Group Investments LLC, Sixth Floor Investors LP and G Force Investments LLC. CDI has raised a total of $100 million since 2004.

This financing enables the company to launch new iCell® iPSC lines as well as iCell Endothelial Cells, iCell Neurons, and iCell Hepatocytes lines for biomedical and pharmaceutical drug development and safety research, as well as continue to increase production capacity for its iCell Cardiomyocytes. CDI also plans to continue to rapidly expand its commercial organization to meet the growing demand for these iPSC-based products.

CDI's market-leading production process, which is unique in the industry, can produce large quantities of human tissue cells while maintaining their purity, quality and consistency. The company's iCell Cardiomyocytes product line is the first commercial product based on stem cells grown from adult tissue using CDI's iPSC technology developed by founder James A. Thomson. CDI grows its fully pluripotent stem cell lines from adult human donor blood samples. The company's iPSC technology coaxes the blood cells to turn back their developmental clock and become iPSCs, which then can be directed to develop into any of the human body's 200+ cell types.

Thomson, CDI Chief Scientific Officer and recent winner of the prestigious Albany Medical Award and King Faisal Award, commented, "Human pluripotent stem cells offer a unique window into human health and biology. I founded CDI based on my desire to make stem cells and human tissue cells widely available in the quantity, quality and purity to enable researchers around the world to accelerate their discoveries in human health and biological research. I am gratified that CDI has been able to secure funding to make this vision a reality."

"CDI continues to maintain its leadership with the highest-level of funding in this new industry," said Robert Palay, the company's Chairman and Chief Executive Officer. "We have strong demand from pharmaceutical companies for our fully functional, live human cells derived from iPSCs, because the high quantity, quality and purity of our cells result in more accurate preclinical drug testing and effective research."

"Prior to our iCell product introduction, our pharmaceutical and research customers could test new drugs and conduct research only on human tissue cells from cadavers, cells derived from tumors or animal cells," said Chris Parker, Chief Commercial Officer of CDI. "None of these cell models accurately mirrors what happens in a live human body. iCell products improve the efficiency and effectiveness of drug discovery and safety testing by enabling in vitro clinical trials on fully functional human cells before drugs are tested on humans."

Palay concluded, "CDI remains committed to offer the broadest array of iPSC-based products in the purest forms and largest quantities available in the market, to allow our customers to speed their discovery of safer more effective drugs and to make advances in other scientific research. The support of our investors and the success of our most recent financing will help us deliver on this commitment."

Leonard Loventhal, an officer of Sixth Floor Investors and a member of CDI's Board of Directors, commented, "CDI has uniquely built industrial expertise in high-volume, high-quality manufacturing of human iPS cell-derived tissue products. When combined with their strong intellectual property position, full freedom to operate, and the capital resources of this investor consortium, CDI is the only company positioned to provide its pharmaceutical customers with iPSC-derived products immediately useful in drug discovery and safety testing."

"We've enjoyed working with CDI's management team again," said Mathew Zell, Managing Director of Equity Group Investments LLC.  "We are impressed with the exciting progress at CDI and are looking forward to the launch of many important, new products."

"We are enthused that Wisconsin has become recognized as a hub for biotechnology and stem cell research," continued Brian Stark, an investor in G Force Investments LLC.  "We believe that the combination of CDI's products, technology and team should result in substantial value creation."

About Cellular Dynamics International

Cellular Dynamics International, Inc. (CDI) is a leading developer and marketer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See

SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
2. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
3. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
4. SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011
5. Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
6. Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF
7. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
8. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
9. Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  Data Science Automation (DSA), ... opening of a new branch office in the ... DSA,s presence in Europe . The decision ... increasing demand for local support of customers in the medical ... Ph.D., DSA,s UK Branch Manager. "We have had tremendous success ...
(Date:10/13/2015)... -- SeraCare Life Sciences, a leading partner to global in ... medicine business unit has launched its second product in ... (NGS)-based tumor profiling assays.  The Seraseq TM Solid ... mutations in key oncogenes and tumor suppressor genes as ... is offered at five additional allele frequencies. ...
(Date:10/13/2015)... , Oct. 13, 2015  Graduate students across ... and medical research, will soon have the opportunity ... care – the drug discovery and development process. ... has collaborated with 10 leaders from academic institutions ... Medicines: The Process of Drug Development."  Lilly will ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to announce that ... March 2nd and 3rd, 2016. The annual meeting, along with the Dallas Rhinoplasty ... around the world. , Key topics at this year's event will include discussions on ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a ... announced today a significant contract that will provide its award-winning private messaging solution ... on the growing success of its Relay program, IBX Wire™, which now has ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the launch of ... train with, participate in local fitness & sporting events, and stay motivated. ... high medical costs drive us to get more serious about fitness and wellness, individuals ...
(Date:10/13/2015)... Boston, MA (PRWEB) , ... October 13, 2015 , ... ... mortar of the body, including muscle, bone, and blood. But how much protein does ... more complicated than it might seem, according to the October 2015 issue of ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Scientists in ... tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted ... , The doctors from PhenoPath Laboratories in Seattle and the University of British Columbia ...
Breaking Medicine News(10 mins):